60/100B82.385
USD
-1.36
(-1.62%)
Post Trading·82.380USD-0.005(-0.01%)
Fair value76.47Plus+8%51Price 82.39119
Q4 FY2026 · Earnings report
EPS estimate 1.55Revenue estimate 5.92B
Q4 FY2026 · Earnings report
EPS estimate 1.55Revenue estimate 5.92B
GE HealthCare Technologies total debt 2020–2026What is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
GE HealthCare Technologies's total debt was 10.41B USD on 30 September 2026, down 3.1% on a year before. At the end of fiscal year 2025 it was 10.00B USD.
Last updated 7 Nov 2026 · Next report 3 Feb 2027
Total debt
Growth
| Fiscal year | Period ending | Total debt | Growth | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 10.41B | -3.14% | 2.85B | -7.55B | 0.90 |
| FY2025 | 31 Dec 2025 | 10.00B | +6.69% | 4.51B | -5.49B | 0.96 |
| FY2024 | 31 Dec 2024 | 9.38B | -4.94% | 2.89B | -6.49B | 1.11 |
| FY2023 | 31 Dec 2023 | 9.86B | +14.22% | 2.50B | -7.36B | 1.38 |
| FY2022 | 31 Dec 2022 | 8.64B | +1,875.97% | 1.45B | -7.19B | 0.92 |
| FY2021 | 31 Dec 2021 | 437.00M | -6.62% | 556.00M | 119.00M | 0.03 |
| FY2020 | 31 Dec 2020 | 468.00M | — | 1.01B | 539.00M | 0.03 |
| Quarter | Period ending | Total debt | Growth on a year before | Cash and short-term investments | Net cash | Debt to equity |
|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 10.41B | -3.14% | 2.85B | -7.55B | 0.90 |
| Q2 FY2026 | 30 Jun 2026 | 10.09B | -6.92% | 2.11B | -7.99B | 0.92 |
| Q1 FY2026 | 31 Mar 2026 | 10.58B | +15.17% | 2.29B | -8.29B | 0.99 |
| Q4 FY2025 | 31 Dec 2025 | 10.00B | +6.69% | 4.51B | -5.49B | 0.96 |
| Q3 FY2025 | 30 Sept 2025 | 10.74B | +0.10% | 4.01B | -6.74B | 1.08 |
| Q2 FY2025 | 30 Jun 2025 | 10.84B | +12.22% | 3.76B | -7.08B | 1.12 |
| Q1 FY2025 | 31 Mar 2025 | 9.18B | -5.01% | 2.47B | -6.71B | 1.00 |
| Q4 FY2024 | 31 Dec 2024 | 9.38B | -4.94% | 2.89B | -6.49B | 1.11 |
| Q3 FY2024 | 30 Sept 2024 | 10.73B | +4.61% | 3.57B | -7.17B | 1.29 |
| Q2 FY2024 | 30 Jun 2024 | 9.66B | -5.63% | 2.01B | -7.65B | 1.24 |
| Q1 FY2024 | 31 Mar 2024 | 9.67B | -5.58% | 2.56B | -7.11B | 1.31 |
| Q4 FY2023 | 31 Dec 2023 | 9.86B | +14.22% | 2.50B | -7.36B | 1.38 |
| Q3 FY2023 | 30 Sept 2023 | 10.26B | — | 2.42B | -7.84B | 1.44 |
| Q2 FY2023 | 30 Jun 2023 | 10.24B | — | 1.94B | -8.30B | 1.44 |
| Q1 FY2023 | 31 Mar 2023 | 10.24B | — | 2.33B | -7.91B | 1.53 |
| Q4 FY2022 | 31 Dec 2022 | 8.64B | — | 1.45B | -7.19B | 0.92 |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
Total debt counts commercial paper, term debt and lease liabilities.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Balance sheet
Common questions about GE HealthCare Technologies's debt
Source: Financial Modeling Prep